e-learning
resources
London 2016
Sunday, 04.09.2016
Features and impact of comorbidities in COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Statistical analysis of anthropometric differences between COPD stages 1 and 2
Stefan A. Mihaicuta (Timisoara, Romania), Stefan A. Mihaicuta, Mihai Udrescu, Izabella-Anita Toth, Lucretia Udrescu, Iosif Marincu
Source:
International Congress 2016 – Features and impact of comorbidities in COPD
Session:
Features and impact of comorbidities in COPD
Session type:
Thematic Poster
Number:
651
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Stefan A. Mihaicuta (Timisoara, Romania), Stefan A. Mihaicuta, Mihai Udrescu, Izabella-Anita Toth, Lucretia Udrescu, Iosif Marincu. Statistical analysis of anthropometric differences between COPD stages 1 and 2. Eur Respir J 2016; 48: Suppl. 60, 651
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Are there any differences between Tunisian and European COPD phenotypes?
Source: International Congress 2016 – Best abstracts in COPD management
Year: 2016
Gender differences in COPD patients
Source: International Congress 2014 – Clinical presentations
Year: 2014
Significance of quantitative radiological phenotypes of COPD on BODE index
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
Evaluation of the GOLD 2011 severity criteria across the COPD spectrum
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
GOLD and phenotypes: The new Czech COPD guidelines
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015
Three year follow-up of distribution and stability of patients with COPD according GOLD 2014
Source: International Congress 2015 – Clinical assessment in asthma and COPD
Year: 2015
Outcomes in patients with COPD during a 3 year follow-up
Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD
Year: 2015
COPD: GOLD 2011 and implications for clinical practice
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013
The relationship between 24-hour symptoms and COPD exacerbations: Results from ASSESS
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Heterogeneity of group D in the new GOLD classification of COPD
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
Phenotypical heterogeneity of severe COPD subjects: Baseline results from the Czech multicentre research database of COPD
Source: International Congress 2015 – Monitoring and phenotyping COPD
Year: 2015
Heterogeneity inside group D COPD patients: About 827 cases
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
Symptom profile of exacerbations in earlier and later COPD
Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes
Year: 2013
CAT in COPD phenotypes (POPE study)
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
The distribution of phenotypes in a population of severe COPD
Source: International Congress 2014 – COPD exacerbations
Year: 2014
RT protocol reduces AECOPD readmissions
Source: International Congress 2016 – In-patient and out-patient COPD management
Year: 2016
Analysis of the frequency of COPD exacerbations in the ’real-life’ DACCORD study over a 2 year period
Source: International Congress 2016 – Comorbidities and exacerbations in COPD
Year: 2016
Clinical and inflammatory characteristics of 'unreported' COPD exacerbations
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Gender differences in hospitalized patients with acute exacerbation of COPD
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
A global survey conducted to determine frequency of exacerbations in COPD patients
Source: Annual Congress 2013 –COPD treatment
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept